Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu

Ítems similars

• Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu
  per: Egbert F Smit, et al.
  Publicat: (2025-07-01)
• Response to: Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study’ by Wang
  per: Egbert F Smit, et al.
  Publicat: (2025-07-01)
• Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’
  per: Xudong Zhu
  Publicat: (2025-03-01)
• Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Smeenk et al
  per: Bi-Cheng Wang
  Publicat: (2025-07-01)
• Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
  per: Hendrikx JJMA, et al.
  Publicat: (2020-10-01)